Growth Metrics

Inmune Bio (INMB) Assets Average (2019 - 2025)

Inmune Bio (INMB) has disclosed Assets Average for 7 consecutive years, with $32.9 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 28.84% to $32.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.9 million through Dec 2025, down 28.84% year-over-year, with the annual reading at $36.0 million for FY2025, 25.53% down from the prior year.
  • Assets Average hit $32.9 million in Q4 2025 for Inmune Bio, down from $35.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $103.8 million in Q4 2021 to a low of $32.9 million in Q4 2025.
  • Historically, Assets Average has averaged $64.1 million across 5 years, with a median of $61.6 million in 2021.
  • Biggest five-year swings in Assets Average: soared 170.89% in 2021 and later tumbled 33.34% in 2024.
  • Year by year, Assets Average stood at $103.8 million in 2021, then decreased by 20.24% to $82.8 million in 2022, then decreased by 27.72% to $59.8 million in 2023, then fell by 22.85% to $46.2 million in 2024, then decreased by 28.84% to $32.9 million in 2025.
  • Business Quant data shows Assets Average for INMB at $32.9 million in Q4 2025, $35.5 million in Q3 2025, and $37.7 million in Q2 2025.